102 related articles for article (PubMed ID: 24790046)
1. [Claudin 1 as a target for anti-hepatitis C virus strategy].
Fukasawa M
Yakugaku Zasshi; 2014; 134(5):635-40. PubMed ID: 24790046
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
[TBL] [Abstract][Full Text] [Related]
3. [Anti-hepatitis C virus strategy targeting host entry factor claudin-1].
Fukasawa M
Uirusu; 2015; 65(2):245-254. PubMed ID: 27760923
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.
Shimizu Y; Shirasago Y; Kondoh M; Suzuki T; Wakita T; Hanada K; Yagi K; Fukasawa M
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437969
[TBL] [Abstract][Full Text] [Related]
5. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.
Paciello R; Urbanowicz RA; Riccio G; Sasso E; McClure CP; Zambrano N; Ball JK; Cortese R; Nicosia A; De Lorenzo C
J Gen Virol; 2016 Jan; 97(1):82-94. PubMed ID: 26519290
[TBL] [Abstract][Full Text] [Related]
6. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.
Mailly L; Xiao F; Lupberger J; Wilson GK; Aubert P; Duong FHT; Calabrese D; Leboeuf C; Fofana I; Thumann C; Bandiera S; Lütgehetmann M; Volz T; Davis C; Harris HJ; Mee CJ; Girardi E; Chane-Woon-Ming B; Ericsson M; Fletcher N; Bartenschlager R; Pessaux P; Vercauteren K; Meuleman P; Villa P; Kaderali L; Pfeffer S; Heim MH; Neunlist M; Zeisel MB; Dandri M; McKeating JA; Robinet E; Baumert TF
Nat Biotechnol; 2015 May; 33(5):549-554. PubMed ID: 25798937
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus induces CD81 and claudin-1 endocytosis.
Farquhar MJ; Hu K; Harris HJ; Davis C; Brimacombe CL; Fletcher SJ; Baumert TF; Rappoport JZ; Balfe P; McKeating JA
J Virol; 2012 Apr; 86(8):4305-16. PubMed ID: 22318146
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
Fofana I; Krieger SE; Grunert F; Glauben S; Xiao F; Fafi-Kremer S; Soulier E; Royer C; Thumann C; Mee CJ; McKeating JA; Dragic T; Pessaux P; Stoll-Keller F; Schuster C; Thompson J; Baumert TF
Gastroenterology; 2010 Sep; 139(3):953-64, 964.e1-4. PubMed ID: 20685314
[TBL] [Abstract][Full Text] [Related]
9. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
[TBL] [Abstract][Full Text] [Related]
10. Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.
Riva L; Song OR; Prentoe J; Helle F; L'homme L; Gattolliat CH; Vandeputte A; Fénéant L; Belouzard S; Baumert TF; Asselah T; Bukh J; Brodin P; Cocquerel L; Rouillé Y; Dubuisson J
J Virol; 2018 May; 92(10):. PubMed ID: 29491159
[TBL] [Abstract][Full Text] [Related]
11. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF
Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099
[TBL] [Abstract][Full Text] [Related]
12. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells.
Ramakrishnaiah V; Thumann C; Fofana I; Habersetzer F; Pan Q; de Ruiter PE; Willemsen R; Demmers JA; Stalin Raj V; Jenster G; Kwekkeboom J; Tilanus HW; Haagmans BL; Baumert TF; van der Laan LJ
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):13109-13. PubMed ID: 23878230
[TBL] [Abstract][Full Text] [Related]
13. Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus.
Yang W; Qiu C; Biswas N; Jin J; Watkins SC; Montelaro RC; Coyne CB; Wang T
J Biol Chem; 2008 Mar; 283(13):8643-53. PubMed ID: 18211898
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum.
Benedicto I; Molina-Jiménez F; Barreiro O; Maldonado-Rodríguez A; Prieto J; Moreno-Otero R; Aldabe R; López-Cabrera M; Majano PL
Hepatology; 2008 Oct; 48(4):1044-53. PubMed ID: 18802961
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
16. GB Virus B and Hepatitis C Virus, Distantly Related Hepaciviruses, Share an Entry Factor, Claudin-1.
Toon K; Kalemera MD; Palor M; Rose NJ; Takeuchi Y; Grove J; Mattiuzzo G
J Virol; 2023 Jul; 97(7):e0046923. PubMed ID: 37310242
[TBL] [Abstract][Full Text] [Related]
17. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.
Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391
[TBL] [Abstract][Full Text] [Related]
18. Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.
Hashimoto Y; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
Ann N Y Acad Sci; 2017 Jun; 1397(1):5-16. PubMed ID: 28415141
[TBL] [Abstract][Full Text] [Related]
19. [Anti-hepatitis C Virus Strategy Targeting the Entry Steps].
Fukasawa M
Yakugaku Zasshi; 2019; 139(1):89-95. PubMed ID: 30606936
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission.
Brimacombe CL; Grove J; Meredith LW; Hu K; Syder AJ; Flores MV; Timpe JM; Krieger SE; Baumert TF; Tellinghuisen TL; Wong-Staal F; Balfe P; McKeating JA
J Virol; 2011 Jan; 85(1):596-605. PubMed ID: 20962076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
